FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 on 30(h) of th or So nv Act of

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burde	en									
hours per response:	0.5									

1. Name and Address of Reporting Person* <u>Preti Robert A</u>			2. Issuer Name and Ticker or Trading Symbol <u>NeoStem, Inc.</u> [NBS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O NEOSTEN 420 LEXINGTO	·	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/19/2011	X Officer (give title Other (specify below) See Remarks					
(Street)		, 30111 430	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
NEW YORK NY 10170			Form filed by More than One Reporting Person						
(City)	(State)	(Zip) Table I - Non-D	Derivative Securities Acquired, Disposed of, or Benef	icially Owned					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivativ Securitie Acquired or Dispos of (D) (Ins 3, 4 and 5	e s (A) sed str.	6. Date Exerc Expiration Da (Month/Day/Y	te			8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options (right to buy)	\$1.5	01/19/2011		A ⁽¹⁾		400,000		(1)	01/18/2021	Common Stock, par value \$0.001 per share	400,000 ⁽¹⁾	\$0	400,000	D	

Explanation of Responses:

1. On January 19, 2011, the commencement date of his employment agreement with Progenitor Cell Therapy, LLC ("PCT"), a wholly-owned subsidiary of NeoStem, Inc. (the "Company"), the reporting person was granted an option to purchase 400,000 shares of common stock, par value \$0.001 per share, of the Company, pursuant and subject to the terms and conditions of the Company's 2009 Equity Compensation Plan. This option is scheduled to vest as to 100,000 shares on each of January 19, 2012, January 19, 2013, January 19, 2014 and January 19, 2015.

Remarks:

President, Progenitor Cell Therapy, LLC, a wholly-owned subsidiary of the Company

Robert A. Preti, By: /s/ Catherine M. Vaczy, Esq., Attorney-in-Fact

01/21/2011

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.